Advanced Medicine

Experts suggest that outsourcing CGT manufacturing capabilities to CDMOs brings additional benefits, although not without challenges

Editas and Azzur Group scale up their efforts against sickle cell disease with experimental gene editing medicine EDIT-301

Here’s why virus-like particles could open a new chapter in combating disease.

Could non-pathogenic viruses provide an unrejectable therapeutic target?

Navigating the cell therapy partnership selection process can be complex. Here, I share the questions you should be asking to help you get it right.

Deputy editor Rob Coker recalls his trip to the labs of Caszyme, Vilnius, where he spoke with CEO Monika Paule about the potential of genome editing

Experts discuss the most promising growth prospects in the cell and gene landscape

While contamination issues continue to limit the potential of gene therapy, scientists can no longer afford to ignore the best detection methods.

Who are the most influential and inspirational people in drug development and manufacturing? Nominations for the Power List 2024 are now open!

Sitting Down With … Tirtha Chakraborty, Chief Scientific Officer at Vor Bio